Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquine in human urine following direct injection.
A sensitive and specific reversed-phase high-performance liquid chromatographic assay was developed for the determination of debrisoquine and 4-hydroxydebrisoquine in urine. The urine samples were directly injected following an ether clean-up step which eliminated interference. Separation of the analytes was achieved using a mobile phase consisting of acetonitrile-methanol-0.02 M heptane sulfonic acid (pH 3.0) (6:37:57) and a mu Bondapak C18 analytical column. The assay utilizes fluorescence detection at 208 nm (ex) and 562 (em). The within-day and between-day coefficients of variation were < or = 10% for both components and accuracy was within 12%. The method is suitable of pharmacogenetic studies utilizing debrisoquine.
Frye
R F
RF
Department of Pharmacy and Therapeutics, School of Pharmacy, University of Pittsburgh, PA 15261, USA.
Branch
R A
RA
D002138:Calibration; D002851:Chromatography, High Pressure Liquid; D003647:Debrisoquin / Q000031:analogs & derivatives* / Q000652:urine; D006801:Humans; D007202:Indicators and Reagents; D011786:Quality Control; D015203:Reproducibility of Results; D013050:Spectrometry, Fluorescence
D007202:Indicators and Reagents; C012359:4-hydroxydebrisoquin; D003647:Debrisoquin